Scinai Immunotherapeutics Ltd. - American Depositary Shares (SCNI)

Competitors to Scinai Immunotherapeutics Ltd. - American Depositary Shares (SCNI)

Bristol-Myers Squibb Company 

Bristol-Myers Squibb is a global leader in immuno-oncology and has a diverse portfolio of proven therapies such as Opdivo and Yervoy. While Scinai focuses on innovative approaches within immunotherapy, BMS has the scale and resources to conduct extensive trials and achieve widespread acceptance in the medical community. This vast experience and financial backing make BMS a formidable competitor, often overshadowing smaller companies like Scinai.

Immunovant, Inc. 

Immunovant specializes in therapies targeting autoimmune diseases and competes in the broader immunotherapy landscape where Scinai operates. Their focus on monoclonal antibodies and established clinical programs provide Immunovant with a more robust clinical pipeline compared to Scinai's relatively earlier-stage developments. This maturity may give Immunovant a significant edge in investor confidence and clinical validation.

Kadmon Holdings, Inc.

Kadmon is focused on the development of therapies for immunology and oncology, which overlaps with some of the therapeutic areas that Scinai Immunotherapeutics targets. Though Kadmon has established products and a more considerable market presence, Scinai's unique approach to immune therapies can appeal to niche markets. Still, Kadmon’s years of experience and industry connections may give them a competitive edge in terms of market reach and commercialization.

Novavax, Inc. 

Novavax is engaged in the development of innovative vaccines to prevent serious infectious diseases. They have a competitive advantage in established vaccine platforms and significant funding and partnerships that allow them to expedite their development processes. In comparison, Scinai Immunotherapeutics focuses on novel immune-oncology therapies, creating distinct niches in the immunotherapy space but competing for funding, research talent, and potential commercial partnerships.

Sorrento Therapeutics, Inc.

Sorrento Therapeutics is involved in the development of treatments for cancer and autoimmune diseases, directly competing in the same therapeutic zones as Scinai Immunotherapeutics. Sorrento’s diversified approach and a broader range of clinical trials provide them a coping mechanism against market uncertainties, while Scinai focuses on more targeted therapies. However, Sorrento's established researcher collaborations and technology platforms give them a competitive advantage in scaling up their products effectively.